Nagendran Sukumar 4

What Happened

• Nagendran Sukumar, President & Head of R&D and a director of Taysha Gene Therapies (TSHA), sold 200,000 shares on July 10, 2026.
• The reported weighted average sale price was $6.24 per share, for total proceeds of approximately $1,248,000. The filing lists the transaction as an open-market or private sale (code S), which is a disposition of shares and is often routine.

Key Details

• Transaction date: July 10, 2026. Report filed the same day (no late filing indicated in the supplied details).
• Price: weighted average $6.24; actual trade prices ranged from $5.99 to $6.52 (footnote F2). The filer can provide a per-price breakdown on request.
• Shares sold: 200,000; total proceeds ≈ $1,248,000.
• Shares owned after transaction: not specified in the information provided.
• Notable footnotes: F1 — sale executed pursuant to a Rule 10b5-1 trading plan adopted June 11, 2025; F2 — weighted average price and per-trade range disclosure.
• Transaction code: S = Sale (disposition).

Context

• The sale was made under a pre-established Rule 10b5-1 plan, which typically schedules trades in advance; this procedural detail limits reading into the insider’s contemporaneous view.
• For retail investors, purchases tend to be more informative about insider sentiment; this filing documents a routine sale by a senior executive under a pre-set plan.